Why are more young adults getting cancer? That's one of the most pressing questions facing the scientific community today. Traditionally thought of as a disease that affects aging populations, recent data shows that cancer diagnoses for people under the age of 50 are increasing. To tackle this problem, it’ll take a global effort. In this episode you’ll hear from patients, oncologists, researchers and health care providers who are coming together to address this issue head on. 

Featured guests:
– Dr. Marshall Anthony Jr., social scientist and colorectal cancer patient
– Dr. Johanna Bendell, Chief Development Officer of Oncology, Pfizer
– Dr. Yin Cao, molecular cancer epidemiologist; Cao Lab leader, Washington University
– Dr. Beatrice Dionigi, colorectal cancer surgeon; founder & co‑director, Early Onset Colon and Rectal Cancer Project, Columbia Research Cancer Center
– Dr. Susan Zhang, Global Development Lead, Pfizer Oncology

Dive into the episode here:
00:00 – A patient story reveals an alarming new trend
6:30 – The data behind the rise of early-onset cancer 
10:39 – The global search for a cause  
14:13 – The unique challenges facing young people with cancer 
20:28 – Screening guidelines and what to expect from a colonoscopy  
25:17 – The importance of early detection  
27:59 – The conclusion of Marshall's cancer journey 
30:23 – What's next, and closing thoughts 

Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Dr. Marshall Anthony Jr. on his colorectal cancer journey.

Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Science Will Win is back for a new season! Dr. Raven Baxter, a molecular biologist also known as Raven the Science Maven, returns as our host to dive into the latest in oncology: The latest challenges, the latest research, the latest treatment approaches, and the latest sources of progress and optimism keeping researchers going. You’ll hear from leading doctors, cutting-edge scientists, insightful historians, and inspiring patients sharing powerful stories of resilience. Plus, for the first time, you can find full length video discussions led by Raven on Pfizer’s YouTube channel. Season 6 of Science Will Win is coming soon—subscribe to stay tuned in! 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In drug discovery and development, every part of the process matters. Scientists learn from every experiment and every observation. In fact, some of the most cutting-edge advancements in medicine are being dreamed up from findings uncovered in the past.  

In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble dive deep into antibody drug conjugates, a groundbreaking modality that uses targeted antibody engineering to deliver potent chemotherapy directly to cancer-causing cells. They explore the complex ADC creation process and learn how ADCs are changing the standard of care for bladder cancer, from someone with a personal relationship to the disease.

Featured Guests:
– Renee Barron-Gores, Caregiver
– Phoenix Ho, Vice President, Oncology Early Clinical Development, Pfizer
– Sharsti Sandall, Executive Director, ADC Biology, Oncology Research Unit, Pfizer

Dive into the episode here:
1:16 - Old ideas yield new discoveries
3:01 - How do antibody drug conjugates work?
5:07 - The origins of ADCs
8:36 - ADCs allow for more targeted cancer treatment
10:44 - How are ADCs structured?
14:16 - How do scientists find the best ADC combinations?
18:27 - Developing oncology drugs
22:02 - ADCs and bladder cancer
24:28 - A caregiver’s perspective on cancer treatment
38:12 - Science Will Win

Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.

Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Protein-protein interactions facilitate numerous bodily processes – everything from the basics of how our muscles contract to the more complex ways cancer can spread through the body. So, what if there was a way to alter some of these interactions? Or even create new ones?

In this episode, we’re diving into the fascinating field of molecular glues, a revolutionary modality on the precipice of changing the treatment landscape for certain cancers and potentially other diseases and conditions. 

Featured Guests:
– Joyann Donaldson, Principal Scientist, Synthesis Group Lead, Pfizer
– Jennifer LaFontaine, Head of Oncology Medicinal Chemistry, Pfizer
– Neal Sach, Research Fellow, Pfizer
– Jillian Spangler, Associate Research Fellow, Pfizer

Dive into the episode here:
0:50 - A metaphor to explain molecular glues
2:36 - How do molecular glues work in the body?
5:57 - A new frontier for cancer treatment 
13:05 - The history behind molecular glues
16:59 - How do scientists design molecular glues?
19:05 - A visit to Pfizer’s La Jolla labs
32:42 - How can molecular glues change the patient experience?
36:42 - Molecular glues beyond cancer treatment

Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.

Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The next frontier of medicine is focused on highly targeted drug therapies that could expand the possibilities of individualized patient care. Today, scientists are working on a particular type of molecule that could harness multiple capabilities and treat inflammatory and autoimmune diseases in ways never done before. 

In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how the latest advancements in antibody engineering led to multispecific antibodies—powerhouse molecules that can do the jobs of multiple drugs in one. They learn all about what it takes to assemble these antibodies and the impact they could make on patients—with a patient.  

Featured Guests:
– Emma Guttman, Chair of the Department of Dermatology, Icahn School of Medicine at Mount Sinai
– Amanda Lopez, Patient, Texas Ambassador for the National Eczema Association
– Laird Bloom, Senior Director of Biomedicine Design, Pfizer
– Thomas Wynn, Vice President of Discovery, Inflammation & Immunology, Pfizer

Dive into the episode here:
1:12 - A metaphor for multispecific antibodies
4:08 - How do multispecific antibodies work?
10:39 - The history behind multispecific antibodies
16:29 - How are multispecific antibody drugs are made?
22:58 - An eczema expert on the potential of multispecific antibodies
29:30 - Amanda Lopez's eczema story
40:14 - What's next, and closing thoughts

Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.

Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Medical advancements don’t just spring up—they happen by building on decades of previous discoveries. Today, one of these advancements might be on the verge of another breakthrough. But what had to happen first for it to exist?

In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how a vaccine candidate for a deadly, once-mysterious bacterial disease came to be. The story takes them from one doctor’s groundbreaking connection in the 70s, all the way to a real lab where vaccines are being developed today.

Featured Guests:
– Carol Baker, Pediatric Infectious Disease Specialist
– Isis Kanevsky, Senior Director, Vaccines, Pfizer
– Ksenia Krylova, Senior Director, Vaccines, Pfizer

Dive into the episode here:
02:54 - Getting into the problem
05:11 - The basics of immunity and vaccine science
09:32 - What is a conjugate vaccine?
14:44 - Group B Strep: A case study
22:23 - Talking to a GBS pioneer
31:40 - A trip to the lab
43:08 - What's next, and closing thoughts

Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.

Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Science Will Win is back for a new season, with new hosts and a new format. Now, science educators Dr. Raven Baxter a molecular biologist otherwise known as Raven, the Science Maven, and Dr. Ronald Gamble, a theoretical astrophysicist at NASA, are teaming up to explore four exciting medical technologies. These technologies are right on the cusp of a potentially groundbreaking moment, either unlocking our ability to tackle new diseases or allowing us to tackle old ones in ways we never could before. This journey takes our hosts through discussions with cutting edge researchers, stories of medical mysteries solved, and tours of real labs that are used every day in the quest to create new medicines. Tune in to the latest four-part season, coming soon!

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Over the last five years, the healthcare industry has witnessed an explosive surge in digital health services, revolutionizing the way we access medical care. Patients today are taking charge of their health journey by using different digital tools to stay on top of their preventative screenings, implement dietary and lifestyle changes, access mental health resources, and so much more. In this conversation, patient advocates and industry leaders from Noom, Thrive, and Pfizer, dive into the potential power of artificial intelligence and the anticipated transformation in personalized health plans. They share real-world examples that highlight how digital technologies are helping patients feel empowered and shape the future of healthcare. 

Through this conversation you heard Lidia Fonseca reference Health Answers by Pfizer. In February 2025, the Pfizer team launched this new platform, powered by generative AI that provides clear, relevant answers to your health & wellness questions and helps you take action for yourself and your loved ones. To learn more, visit healthanswers.pfizer.com.

Moderator:
Stephanie Agresta, Managing Director, Ascendancy Events 

Featured experts:
-Karin Bilich, Head of Content, Noom 
-Lidia Fonseca, Chief Digital & Technology Officer, Pfizer 
-MT Grant, SVP & GM, Thrive for Health

This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge.

Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

While cancer deaths in the United States have declined in recent years, some populations are being left behind—facing complicated challenges to accessing the care they need. Intervening at the earliest stages of disease onset is critical to cancer treatment success and to reducing the risk of recurrence. So how do we create a world where all people with cancer are quickly diagnosed and can live better, longer lives as science advances? In this conversation, patient advocates and healthcare leaders from Pfizer, the American Cancer Society, and the Healthcare Businesswomen’s Association, discuss the power of collaboration in the effort to “Outdo Cancer.”

Moderator
• Tyrone McClain, Senior Director, Public Affairs, Pfizer
Speakers
• Carmen White, U.S. & Global Oncology Health Equity Lead, Pfizer
• Pam Traxel, American Cancer Society, Cancer Action Network
• Mary Stutts, CEO, Healthcare Businesswomen's Association (HBA)

This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge.

Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Podcasting has become essential for communicating breakthroughs in science, offering an accessible and engaging platform to reach diverse audiences. This evolving medium fosters deeper connections by delivering trusted information in accessible and compelling ways. In this conversation, audio makers from Pfizer, Acast, and TED, discuss what it takes to stand out in the science podcast space, insights on strategy, and how they're working to shape the future of health communication.

Moderator
• Aaron Strout, Former CMO of Real Chemistry and Health Podcaster

Speakers
• Erica Santiago, Executive/Digital Communications & Podcast Strategy, Pfizer
• Veronika Taylor, SVP of Acast’s Creator Network
• Shoshana Ungerleider MD, Host and Producer of TED Health Podcast

This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge.

Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.